148 related articles for article (PubMed ID: 20102555)
1. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population.
Mitra D; Davis KL; Beam C; Medjedovic J; Rustgi V
Value Health; 2010; 13(4):479-86. PubMed ID: 20102555
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
[TBL] [Abstract][Full Text] [Related]
4. Assessment and utilization of rapid virologic response in US veterans with chronic hepatitis C: evaluating provider adherence to practice guidelines.
Hwang EW; Thomas IC; Cheung R; Backus LI
J Clin Gastroenterol; 2013 Mar; 47(3):264-70. PubMed ID: 23269309
[TBL] [Abstract][Full Text] [Related]
5. Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin.
Brixner DI; Ye X; Chu TC; Blumentals WA; Hassanein TI
Am J Health Syst Pharm; 2009 Dec; 66(24):2171-8. PubMed ID: 19966085
[TBL] [Abstract][Full Text] [Related]
6. Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009.
Gheorghe L; Pascu O; Ceausu E; Csiki IE; Iacob S; Caruntu F; Simionov I; Vadan R
J Gastrointestin Liver Dis; 2010 Jun; 19(2):161-7. PubMed ID: 20593049
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
8. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
10. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
Stahmeyer JT; Krauth C; Bert F; Pfeiffer-Vornkahl H; Alshuth U; Hüppe D; Mauss S; Rossol S
J Viral Hepat; 2016 Feb; 23(2):105-15. PubMed ID: 26411532
[TBL] [Abstract][Full Text] [Related]
11. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients.
Solomon M; Bonafede M; Pan K; Wilson K; Beam C; Chakravarti P; Spiegel B
Dig Dis Sci; 2011 Oct; 56(10):3024-31. PubMed ID: 21717127
[TBL] [Abstract][Full Text] [Related]
12. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Nakano S; Arakawa T
Liver Int; 2009 Jan; 29(1):120-5. PubMed ID: 18384519
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of peginterferon alpha-2a and peginterferon alpha-2b combination regimens in genotype-1 naive patients with chronic hepatitis C.
Gheorghe L; Baculea S
Hepatogastroenterology; 2010; 57(101):939-44. PubMed ID: 21033255
[TBL] [Abstract][Full Text] [Related]
14. Economic burden associated with patients diagnosed with hepatitis C.
McCombs JS; Yuan Y; Shin J; Saab S
Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
[TBL] [Abstract][Full Text] [Related]
15. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
Kim DY; Yoon KT; Kim W; Lee JI; Hong SH; Lee D; Jang JW; Choi JW; Kim I; Paik YH
Medicine (Baltimore); 2016 Jul; 95(30):e3896. PubMed ID: 27472670
[TBL] [Abstract][Full Text] [Related]
16. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
[TBL] [Abstract][Full Text] [Related]
17. Making it happen: managed care considerations in vanquishing hepatitis C.
McHutchison JG; Bacon BR; Owens GS
Am J Manag Care; 2007 Dec; 13 Suppl 12():S327-36; quiz S337-40. PubMed ID: 18095781
[TBL] [Abstract][Full Text] [Related]
18. Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus.
De Compadri P; Koleva D; Mangia A; Motterlini Stat Sci N; Garattini L
J Med Econ; 2008; 11(1):151-63. PubMed ID: 19450116
[TBL] [Abstract][Full Text] [Related]
19. [A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C].
Kim MN; Yoon KT; Park JY; Kim DY; Ahn SH; Chon CY; Han KH
Korean J Hepatol; 2009 Dec; 15(4):496-503. PubMed ID: 20037268
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
García-Contreras F; Nevárez-Sida A; Constantino-Casas P; Abud-Bastida F; Garduño-Espinosa J
Arch Med Res; 2006 Jul; 37(5):663-73. PubMed ID: 16740439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]